What Is The Forecast Valuation Of The Global Vasoactive Intestinal Peptide Tumor Market Projected To Reach $2.03 Billion By 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Will The Vasoactive Intestinal Peptide Tumor Market Valuation Change Between Now And 2029?
In the past few years, the market size for vasoactive intestinal peptide tumors has seen robust growth. It is anticipated to expand from $1.51 billion in 2024 to $1.61 billion in 2025, marking a compound annual growth rate (CAGR) of 6.3%. The notable progression during the historical period is due to a rise in occurrences of VIP tumors, heightened attention to R&D endeavors, increased awareness around healthcare, the development of healthcare infrastructure, and partnerships between biotech companies and research organizations.
The market size of the vasoactive intestinal peptide tumor is predicted to witness robust growth in the coming years, with an anticipated value of $2.03 billion by 2029 at a compound annual growth rate (CAGR) of 6.1%. This surge in growth during the forecast period is expected due to factors such as augmenting demand for chemotherapy, swift approvals of new medicines, increased need for oral drugs, heightened awareness about the disease, and a rising occurrence of tumors. Key trends for the forecast period incorporate the progression of targeted therapies, improvements in diagnostic methods, advancements in treatment strategies, personalization in medicine, targeted therapies, and inventive product launches.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23561&type=smp
What Underlying Factors Are Supporting The Vasoactive Intestinal Peptide Tumor Market Growth?
The vasoactive intestinal peptide tumor market is likely to experience growth due to the increased adoption of targeted therapy. Targeted treatments specifically target molecules or pathways that play important roles in disease advancement, especially in cancer, and aim to selectively attack abnormal cells while causing minimum harm to healthy cells. The surge in the use of such therapies is a result of precision medicine which improves effectiveness by concentrating on specific genetic mutations while restricting side effects. To treat VIP tumors, key pathways that stimulate tumor growth and hormone release are blocked by targeted therapies. This action results in a decrease in VIP levels, alleviating symptoms such as severe diarrhea and decelerating the progression of the disease. As a case in point, the American Society of Gene and Cell Therapy (ASGCT), a professional membership organization based in the US, reported in July 2024 that there had been an initiation of 76 gene therapy trials in the second quarter of 2024 showing a 25% increase from the preceding quarter. Hence, the upswing in the use of targeted therapy is accelerating the growth of the vasoactive intestinal peptide tumor market.
Which Sub-Segments Are Driving Growth Within The Vasoactive Intestinal Peptide Tumor Market?
The vasoactive intestinal peptide tumormarket covered in this report is segmented –
1) By Treatment: Surgical Intervention; Radiotherapy; Chemotherapy; Targeted Therapy
2) By Diagnosis: Imaging Techniques; Biopsy; Endoscopic Ultrasound
3) By Therapeutic Approach: Palliative Care; Curative Treatment; Adjuvant Treatment
4) By End-User: Hospitals; Cancer Specialty Clinics; Diagnostic Laboratories
Subsegments:
1) By Surgical Intervention: Tumor Resection; Debulking Surgery; Minimally Invasive Surgery
2) By Radiotherapy: External Beam Radiation Therapy (EBRT); Stereotactic Body Radiation Therapy (SBRT); Proton Therapy
3) By Chemotherapy: Cytotoxic Chemotherapy; Combination Chemotherapy; Adjuvant And Neoadjuvant Chemotherapy
4) By Targeted Therapy: Somatostatin Analog Therapy; Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies
What Future-Focused Trends Are Anticipated In The Vasoactive Intestinal Peptide Tumor Market?
Significant companies involved in the vasoactive intestinal peptide tumor market are prioritizing the development of superior products like long-acting injectable suspensions. The goal is to boost the effectiveness of treatment, improve patients’ adherence to medication routines, and provide continuous relief from symptoms. Long-acting injectable suspensions are a type of drug designed to gradually discharge their active components over a prolonged period, thereby lessening the requirement for regular dosing. Case in point, in October 2024, Teva Pharmaceutical Industries Ltd., a pharmaceutical firm based in the U.S, launched the only generic variant of Sandostatin LAR Depot (octreotide acetate for injectable suspension) in the U.S market. This drug is utilized for long-term maintenance treatment in acromegalic patients who have shown inadequate response to surgical procedures or radiotherapy. Moreover, it offers treatment for extreme diarrhea and flushing related to metastatic carcinoid tumors and VIP-secreting tumors. With this launch, Teva demonstrates its prowess in complicated generics, furthering its intent to keep a robust footprint in the generics pharmaceuticals market.
Which Companies Hold A Competitive Edge In The 1661 Market?
Major companies operating in the vasoactive intestinal peptide tumor market are Pfizer Inc., Novartis AG, Mayo Clinic, Labcorp Holdings Inc., Mount Sinai Hospital, Cleveland Clinic Laboratories, Penn Medicine, Stanford Health Care, UCSF Health, ARUP Laboratories, Dr. Lal PathLabs, Cancer Research UK, Medicover Hospitals, NuView Life Sciences Inc., DNA Labs India, Inter Science Institute, Ulta Lab Tests, True Health Labs, Ganesh Diagnostic, Agilus Diagnostics.
Access The Complete Report Here:
Which Region Dominates The Vasoactive Intestinal Peptide Tumor Market Today?
North America was the largest region in the vasoactive intestinal peptide tumor market in 2024. The regions covered in the vasoactive intestinal peptide tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=23561&type=smp
Browse Through More Reports Similar to the Global Vasoactive Intestinal Peptide Tumor Market 2025, By The Business Research Company
Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2025
Tumor Infiltrating Lymphocytes Global Market Report 2025
Solid Tumor Cancer Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
